Primary lung cancer is one of the most common cancers with high morbidity and mortality, and is mainly grouped into small cell lung cancer (SCLC; 20-30%) and non-small cell lung cancer (NSCLC; 70-80%) which include lung squamous carcinoma (LUSC) and lung adenocarcinoma (LUAD). LUAD has different biological behavior relative to LUSC, and is the most common subtype to be diagnosed in people who have never smoked.
Differences in biological behavior, prognosis, and response to treatment have been reported by sex and hormonal status between LUSC and LUAD. Recent advances in the identification of driver mutations in NSCLC result in a number of targeted therapies, which have shaped the current therapeutic strategies and brought survival benefits to patients. Nevertheless, the overall survival of LUAD patients remains low. The identification of new molecular targets and diagnostic or therapeutic biomarkers is vital because one of the major challenges to finding new treatments is the lack of effective targets and biomarkers.
Multiomics integrative analysis is an effective strategy to identify cancer biomarkers and new therapeutic targets for predictive, preventive, and personalized medicine (3P medicine) in LUAD. This Research Topic will focus on, but is not limited to, the use of multi-omics strategies to discover new driver genes, establish prognostic models, and explore therapeutic and diagnosis targets for LUAD patients. We are especially interested in any manuscript in the following aspects:
1. New driver genes and new mutations identified in LUAD,
2. New Risk factors in individual and combined effects lead to LUAD,
3. New diagnostic biomarkers and prognostic models established for LUAD,
4. New therapeutic targets identified for LUAD,
5. New molecular mechanisms and the key signalling pathways for LUAD,
6. Multi-site combination therapy targets and strategies for LUAD.
Primary lung cancer is one of the most common cancers with high morbidity and mortality, and is mainly grouped into small cell lung cancer (SCLC; 20-30%) and non-small cell lung cancer (NSCLC; 70-80%) which include lung squamous carcinoma (LUSC) and lung adenocarcinoma (LUAD). LUAD has different biological behavior relative to LUSC, and is the most common subtype to be diagnosed in people who have never smoked.
Differences in biological behavior, prognosis, and response to treatment have been reported by sex and hormonal status between LUSC and LUAD. Recent advances in the identification of driver mutations in NSCLC result in a number of targeted therapies, which have shaped the current therapeutic strategies and brought survival benefits to patients. Nevertheless, the overall survival of LUAD patients remains low. The identification of new molecular targets and diagnostic or therapeutic biomarkers is vital because one of the major challenges to finding new treatments is the lack of effective targets and biomarkers.
Multiomics integrative analysis is an effective strategy to identify cancer biomarkers and new therapeutic targets for predictive, preventive, and personalized medicine (3P medicine) in LUAD. This Research Topic will focus on, but is not limited to, the use of multi-omics strategies to discover new driver genes, establish prognostic models, and explore therapeutic and diagnosis targets for LUAD patients. We are especially interested in any manuscript in the following aspects:
1. New driver genes and new mutations identified in LUAD,
2. New Risk factors in individual and combined effects lead to LUAD,
3. New diagnostic biomarkers and prognostic models established for LUAD,
4. New therapeutic targets identified for LUAD,
5. New molecular mechanisms and the key signalling pathways for LUAD,
6. Multi-site combination therapy targets and strategies for LUAD.